pneumococcal disease

Merck strides onto Pfizer’s turf, posting pivotal vaccine data and heading to regulators
Merck strides onto Pfizer’s turf, posting pivotal vaccine data and heading to regulators
Fierce Pharma
Merck
Pfizer
vaccines
clinical trials
pneumococcal disease
V116
Prevnar 20
Flag link:
Pfizer takes scalpel to early-phase pipeline, slicing off RSV, eczema, sickle cell and cancer programs
Pfizer takes scalpel to early-phase pipeline, slicing off RSV, eczema, sickle cell and cancer programs
Fierce Biotech
Pfizer
RSV
sickle cell disease
pneumococcal disease
cancer
Flag link:
Merck’s next-gen pneumococcal vaccine strides forward after two phase 3 wins
Merck’s next-gen pneumococcal vaccine strides forward after two phase 3 wins
Fierce Biotech
Merck
pneumococcal disease
vaccines
clinical trials
V116
Flag link:
Pfizer wins FDA nod for Prevnar 20 pneumonia vaccine in children
Pfizer wins FDA nod for Prevnar 20 pneumonia vaccine in children
Seeking Alpha
Pfizer
vaccines
FDA
Prevnar 20
pneumococcal disease
pediatric
Flag link:
Vaxcyte Up on Pneumococcal Conjugate Vaccine Data
Vaxcyte Up on Pneumococcal Conjugate Vaccine Data
Zacks.com
Vaxcyte
vaccines
clinical trials
pneumococcal disease
VAX-24
Flag link:
Vaxcyte strengthens case for experimental pneumococcal vaccine
Vaxcyte strengthens case for experimental pneumococcal vaccine
BioPharma Dive
Vaxcyte
vaccines
clinical trials
pneumococcal disease
Flag link:
After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win
After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win
Endpoints
Vaxcyte
vaccines
VAX-24
pneumococcal disease
Pfizer
Prevnar 20
clinical trials
Flag link:
Pfizer's 20-valent pneumococcal vaccine hits goal in infant trial, teeing up 2022 approval filing
Pfizer's 20-valent pneumococcal vaccine hits goal in infant trial, teeing up 2022 approval filing
Fierce Biotech
Pfizer
vaccines
Prevnar 20
FDA
infants
clinical trials
pneumococcal disease
Flag link:
Big pharma’s key third-quarter data
Big pharma’s key third-quarter data
EP Vantage
GSK
Roche
Pfizer
JNJ
AstraZeneca
Novo Nordisk vaccines
clinical trials
pneumococcal disease
crovalimab
rheumatoid arthritis
Flag link:
Merck outflanks Pfizer's 20-valent shot with pneumococcal vaccine approval for kids
Merck outflanks Pfizer's 20-valent shot with pneumococcal vaccine approval for kids
Endpoints
Merck
FDA
vaccines
pneumococcal disease
Vaxneuvance
Pfizer
Flag link:
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development
BioSpace
Merck
Emergent BioSolutions
Affinivax
Ocugen
vaccines
chikungunya virus
pneumococcal disease
COVID-19
Flag link:
GSK acquiring Affinivax and its next-generation pneumonia vaccine for $2.1 billion upfront
GSK acquiring Affinivax and its next-generation pneumonia vaccine for $2.1 billion upfront
BioPharma Dive
GSK
M&A
Affinivax
vaccines
pneumococcal disease
Flag link:
Merck wins breakthrough therapy designation for potential pneumococcal vaccine successor
Merck wins breakthrough therapy designation for potential pneumococcal vaccine successor
Endpoints
Merck
vaccines
pneumococcal disease
V116
FDA
Flag link:
Merck, amid pneumococcal vaccine race with Pfizer, suffers FDA delay for key pediatric use
Merck, amid pneumococcal vaccine race with Pfizer, suffers FDA delay for key pediatric use
Fierce Pharma
Merck
Pfizer
vaccines
pneumococcal disease
Vaxneuvance
FDA
pediatric
Flag link:
Sanofi aims to double vaccine sales by 2030, citing RSV and flu market expansion as key drivers
Sanofi aims to double vaccine sales by 2030, citing RSV and flu market expansion as key drivers
Fierce Pharma
Sanofi
vaccines
RSV
Flu
MRNA
pneumococcal disease
Flag link:
Bill and Melinda Gates Foundation backs little-known biotech going after Pfizer, Merck on pneumococcal vaccine
Bill and Melinda Gates Foundation backs little-known biotech going after Pfizer, Merck on pneumococcal vaccine
Endpoints
Gates Foundation
vaccines
Inventprise
IVT-25
pneumococcal disease
Flag link:
Pfizer, Merck next-gen pneumococcal vaccines score key CDC panel's backing on way to rival rollouts
Pfizer, Merck next-gen pneumococcal vaccines score key CDC panel's backing on way to rival rollouts
Fierce Pharma
Pfizer
Merck
pneumococcal disease
vaccines
Prevnar 20
Vaxneuvance
CDC
Flag link:
Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine
Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine
Motley Fool
Pfizer
Merck
vaccines
pneumococcal disease
Flag link:
Merck will pay royalties on next-gen pneumococcal shot to settle Pfizer patent fight
Merck will pay royalties on next-gen pneumococcal shot to settle Pfizer patent fight
Fierce Pharma
Merck
Pfizer
FDA
vaccines
pneumococcal disease
patents
Flag link:
Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?
Can Merck Beat Pfizer in This Multibillion-Dollar Vaccine Market?
Motley Fool
Merck
Pfizer
vaccines
Vaxneuvance
Prevnar 20
pneumococcal disease
Flag link:

Pages